CING (Cingulate) Total Receivables: $0.05 Mil (As of Mar. 2026)


CING Cingulate Inc CING
33 GF Score
Price $4.94
! 1 Warning Sign
View Full Analysis

What is Cingulate Total Receivables?

Cingulate CING +4.20% 33 Total Receivables is $0.05 Mil as of Mar. 2026. GuruFocus rates CING with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Cingulate's Total Receivables for the quarter that ended in Mar. 2026 was $0.05 Mil.

Cingulate Total Receivables Historical Data

* Premium members only.

The historical data trend for Cingulate's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate Total Receivables Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.69 0.23 0.02 0.03 0.01

Cingulate Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.02 0.02 0.01 0.05
CING
33GF Score
Cingulate Inc CING
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cingulate Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.05 Mil mean?
Cingulate (CING) has a Total Receivables of $0.05 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Cingulate and its competitors.
Is Cingulate's Total Receivables too high?
Cingulate's current Total Receivables is $0.05 Mil. Overall, Cingulate has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Total Receivables compare to TIL and XLO?
Cingulate's Total Receivables of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Cingulate and its competitors. Cingulate's current Total Receivables is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Total Receivables of $0.05 Mil. The current Total Receivables is $0.05 Mil. Cingulate's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Cingulate (CING), the current Total Receivables is $0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
33GF Score

Get the complete analysis for CING

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.94
Price